GlyTherix Ltd is proud to announce a strategic supply agreement with Isotopia Molecular Imaging Ltd for the provision of Lutetium-177 (Lu-177) and Terbium-161 (Tb-161), key radioisotopes for advancing our targeted radiopharmaceutical therapies.
This collaboration strengthens our ability to develop innovative cancer treatments and reinforces our commitment to delivering cutting-edge solutions to patients worldwide. Isotopia’s expertise in isotope production ensures a reliable and high-quality supply, supporting GlyTherix’s mission to transform precision oncology.
Together, we are pushing the boundaries of radiopharmaceutical innovation and building the next generation of cancer care.